

### Intermittent Oral Dosing of Roxadustat in Peritoneal ...

https://pubmed.ncbi.nlm.nih.gov/31222951

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open-label, 24-week study....

Cited by: 14 Author: Tadao Akizawa, Tetsuro Otsuka, Michael ...

Publish Year: 2020


### Intermittent Oral Dosing of Roxadustat in Peritoneal ...

https://onlinelibrary.wiley.com/doi/full/10.1111/1744-9987.12888

Jun 20, 2019 - The efficacy results of this study are consistent with previous findings that showed that roxadustat is effective in improving anemia in both non-dialysis-dependent 11, 13, 14 CKD and...

Cited by: 14 Author: Tadao Akizawa, Tetsuro Otsuka, Michael ...

Publish Year: 2020



Feedback

### Roxadustat for anemia in patients with end-stage renal ...

https://academic.oup.com/ndt/advance-article/doi/10.1093/ndt/gfab051/6149078 -

Feb 25, 2021 · We evaluated the efficacy and safety of roxadustat vs. epoetin alfa for the treatment of chronic kidney disease (CKD) related anemia in patients new to dialysis. Methods This was a phase ...

#### Roxadustat for anemia in patients with end-stage renal ...

https://www.researchgate.net/publication/349619949...

Mar 02, 2021 · Background We evaluated the efficacy and safety of roxadustat vs. epoetin alfa for the treatment of chronic kidney disease (CKD) related anemia in patients new to dialysis.

### Efficacy of roxadustat in the treatment of peritoneal dialysis patien







ALL

IMAGES

**VIDEOS** 

13,500 Results

Any time ▼

### Evaluation of Efficacy and Safety of Roxadustat in the ... https://clinicaltrials.gov/ct2/show/NCT02273726 •

Oct 24, 2014 · Treatment: Official Title: A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis: Study Start Date: December 2014: Actual Primary Completion Date: September 19, 2018: Actual Study ...

Actual Enrollment: 741 participants Allocation: Randomized

Intervention Model: Parallel Assignment Study Type: Interventional (Clinical Trial)

# Intermittent Oral Dosing of Roxadustat in Peritoneal ...

https://pubmed.ncbi.nlm.nih.gov/31222951

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open-label, 24-week study investigated the efficacy and safety of roxadustat in Japanese CKD patients with anemia on peritoneal

Cited by: 25 Author: Tadao Akizawa, Tetsuro Otsuka, Michael...

Publish Year: 2020




Feedback

# Treatment of Renal Anemia with Roxadustat: Advantages ...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154284

Jan 10, 2020 · There are currently more than 15 phase 3 clinical trials and a target enrollment of about 10,000 patients worldwide studying the safety, efficacy, and long-term effects of roxadustat in CKD



### Efficacy of roxadustat in the treatment of peritoneal dialysis patien





Feedba

ALL

IMAGES

**VIDEOS** 

13,500 Results

Any time ▼

## Evaluation of Efficacy and Safety of Roxadustat in the ...

https://clinicaltrials.gov/ct2/show/NCT02273726 •

Oct 24, 2014 · Treatment: Official Title: A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) in the Maintenance Treatment of Anemia in Subjects With End Stage Renal Disease (ESRD) on Stable Dialysis: Study Start Date: December 2014: Actual Primary Completion Date: September 19, 2018: Actual Study ...

Actual Enrollment: 741 participants Allocation: Randomized

Intervention Model: Parallel Assignment Study Type: Interventional (Clinical Trial)

## Intermittent Oral Dosing of Roxadustat in Peritoneal ...

https://pubmed.ncbi.nlm.nih.gov/31222951

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open-label, 24-week study investigated the efficacy and safety of roxadustat in Japanese CKD patients with anemia on peritoneal di ...

Cited by: 25 Author: Tadao Akizawa, Tetsuro Otsuka, Michael ...

Publish Year: 2020

# PEOPLE ALSO ASK How is Roxadustat used in chronic kidney disease? Are there any phase 2 trials for Roxadustat? Which is better for anemia epoetin alfa or Roxadustat? How is Roxadustat used to treat anemia in China?

# The efficacy and safety of roxadustat for anemia in ...

https://pubmed.ncbi.nlm.nih.gov/33051677

Background: Chronic kidney disease (CKD) is an increasing public health issue. Anemia, which is a complication of CKD, is associated with reduced quality of life and increased morbidity and mortality.